Speaker illustration

Doctor Moritz Jens Hundertmark

University Hospital of Wurzburg, Wurzburg (Germany)

Member of:

European Society of Cardiology

Following international medical education in Switzerland and South Africa, Dr. Hundertmark started cardiology training in 2013. He finished his MD in 2014 which investigated a mutation in a transcriptional co-activator causing Dilated Cardiomyopathy in affected patients. During his clinical training he became site investigator for multiple clinical trials. In 2017, he decided to pursue his interest in clinical research and molecular imaging by enrolling for a Dphil (PhD) in Oxford (UK) which he finished in 2022. His latest interest is devoted to more intense clinical HF expertise which is why he is currently enrolled in the HFA’s 5th Postgraduate Course in Heart Failure

A phase 2a trial investigating ninerafaxstat - a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE)

Event: ESC Congress 2022

Topic: Myocardial Disease

Session: CMR in the evaluation of cardiomyopathies and heart failure


Patients with heart failure with mid-range and reduced left ventricular ejection fraction show similar derangement of cardiac energy and lipid metabolism

Event: ESC Congress 2018

Topic: Heart Failure with Mid-Range Ejection Fraction (HFmrEF)

Session: Chronic heart failure – Pathophysiology and mechanisms


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb